AcuCort Past Earnings Performance

Past criteria checks 0/6

AcuCort's earnings have been declining at an average annual rate of -14.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 22% per year.

Key information

-14.1%

Earnings growth rate

7.0%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate22.0%
Return on equity-29.2%
Net Margin-202.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How AcuCort makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:NV5 Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247-1450
30 Jun 247-1550
31 Mar 247-1450
31 Dec 237-1450
30 Sep 236-13-60
30 Jun 235-1450
31 Mar 235-1540
31 Dec 225-1540
30 Sep 225-14140
30 Jun 225-1330
31 Mar 224-1330
31 Dec 213-1130
30 Sep 211-1030
30 Jun 211-930
31 Mar 211-820
31 Dec 202-820
30 Sep 206-8-20
30 Jun 205-900
31 Mar 205-920
31 Dec 194-830
30 Sep 190-880
30 Jun 190-660
31 Mar 190-660
31 Dec 180-660
30 Sep 180-550
30 Jun 180-550
31 Mar 180-550
31 Dec 170-550
30 Sep 170-550
30 Jun 170-440
31 Mar 170-330
31 Dec 160-220
31 Dec 150-220
31 Dec 140-330

Quality Earnings: NV5 is currently unprofitable.

Growing Profit Margin: NV5 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NV5 is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.

Accelerating Growth: Unable to compare NV5's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NV5 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: NV5 has a negative Return on Equity (-29.16%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 02:13
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AcuCort AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution